相似文献
1
Why doesn't imatinib cure chronic myeloid leukemia?
Oncologist. 2010;15(2):182-6. doi: 10.1634/theoncologist.2009-0297. Epub 2010 Feb 2.
2
ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11.
3
[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Ai Zheng. 2004 Dec;23(12):1696-9.
4
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Blood. 2005 May 15;105(10):3995-4003. doi: 10.1182/blood-2004-09-3534. Epub 2005 Jan 18.
5
Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Acta Haematol. 2012;127(3):152-5. doi: 10.1159/000333107. Epub 2012 Jan 27.
6
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. doi: 10.2146/ajhp070482.
7
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Int J Hematol. 2004 Jun;79(5):411-9. doi: 10.1532/ijh97.04054.
8
Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Curr Opin Hematol. 2004 Jan;11(1):35-43. doi: 10.1097/00062752-200401000-00006.
9
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Med Oncol. 2004;21(4):349-58. doi: 10.1385/MO:21:4:349.
10
Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
Leuk Lymphoma. 2008 Jun;49(6):1022-3. doi: 10.1080/10428190802074635.
引用本文的文献
1
Metabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring.
Metabolites. 2025 Jun 6;15(6):376. doi: 10.3390/metabo15060376.
2
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition.
Front Pharmacol. 2023 Apr 12;14:1183052. doi: 10.3389/fphar.2023.1183052. eCollection 2023.
3
Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.
J Exp Pharmacol. 2021 Aug 17;13:817-857. doi: 10.2147/JEP.S236743. eCollection 2021.
4
A Broad Overview of Signaling in -Negative Classic Myeloproliferative Neoplasms.
Cancers (Basel). 2021 Feb 26;13(5):984. doi: 10.3390/cancers13050984.
5
The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
J Cardiovasc Pharmacol Ther. 2019 Jul;24(4):334-354. doi: 10.1177/1074248419829172. Epub 2019 Feb 17.
6
FZD7 regulates BMSCs-mediated protection of CML cells.
Oncotarget. 2016 Feb 2;7(5):6175-87. doi: 10.18632/oncotarget.6742.
7
Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
PLoS One. 2015 Feb 3;10(2):e0116880. doi: 10.1371/journal.pone.0116880. eCollection 2015.
8
Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia.
Oncoscience. 2014 Jul 23;1(7):510-21. doi: 10.18632/oncoscience.65. eCollection 2014.
9
Pathways in pulmonary arterial hypertension: the future is here.
Eur Respir Rev. 2012 Dec 1;21(126):321-7. doi: 10.1183/09059180.00004812.
10
Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.
Blood Cancer J. 2011 Sep;1(9):e36. doi: 10.1038/bcj.2011.35. Epub 2011 Sep 30.
本文引用的文献
1
A progenitor cell origin of myeloid malignancies.
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16616-21. doi: 10.1073/pnas.0908107106. Epub 2009 Sep 21.
2
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Cancer Res. 2009 Aug 15;69(16):6546-55. doi: 10.1158/0008-5472.CAN-09-0605. Epub 2009 Aug 4.
3
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder.
Cancer Cell. 2009 Aug 4;16(2):137-48. doi: 10.1016/j.ccr.2009.06.007.
4
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
PLoS One. 2009 Jul 16;4(7):e6257. doi: 10.1371/journal.pone.0006257.
5
Stem-cell driven cancer: "hands-off" regulation of cancer development.
Cell Cycle. 2009 May 1;8(9):1314-8. doi: 10.4161/cc.8.9.8217. Epub 2009 May 18.
6
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence.
Leukemia. 2009 May;23(5):892-9. doi: 10.1038/leu.2008.392. Epub 2009 Jan 22.
7
Translation of the Philadelphia chromosome into therapy for CML.
Blood. 2008 Dec 15;112(13):4808-17. doi: 10.1182/blood-2008-07-077958.
8
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Br J Haematol. 2008 Jul;142(3):361-78. doi: 10.1111/j.1365-2141.2008.07197.x. Epub 2008 Jun 5.
9
Chronic myeloid leukemia stem cells.
J Clin Oncol. 2008 Jun 10;26(17):2911-5. doi: 10.1200/JCO.2008.17.5745.
10
PML targeting eradicates quiescent leukaemia-initiating cells.
Nature. 2008 Jun 19;453(7198):1072-8. doi: 10.1038/nature07016. Epub 2008 May 11.
Zotero 插件